 Parameswaran Venugopal
Concepts (225)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antineoplastic Combined Chemotherapy Protocols | 19 | 2023 | 378 | 1.950 |
Why?
| | Leukemia, Myeloid, Acute | 5 | 2021 | 49 | 1.330 |
Why?
| | Lymphoma, Non-Hodgkin | 8 | 2019 | 55 | 1.300 |
Why?
| | Arabinonucleosides | 4 | 2021 | 7 | 1.090 |
Why?
| | Lymphoma | 3 | 2023 | 62 | 1.050 |
Why?
| | Central Nervous System Neoplasms | 3 | 2023 | 21 | 1.040 |
Why?
| | Antibodies, Monoclonal | 8 | 2011 | 293 | 1.040 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 6 | 2019 | 49 | 1.040 |
Why?
| | Antineoplastic Agents | 5 | 2022 | 244 | 0.850 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 11 | 2017 | 47 | 0.840 |
Why?
| | Adenine Nucleotides | 2 | 2010 | 6 | 0.770 |
Why?
| | Burkitt Lymphoma | 3 | 2021 | 12 | 0.620 |
Why?
| | Paraproteinemias | 2 | 2019 | 5 | 0.600 |
Why?
| | Insulin-Like Growth Factor Binding Proteins | 1 | 2015 | 15 | 0.540 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2015 | 62 | 0.520 |
Why?
| | Treatment Outcome | 18 | 2021 | 4036 | 0.470 |
Why?
| | Middle Aged | 25 | 2023 | 11219 | 0.460 |
Why?
| | Adult | 21 | 2021 | 9848 | 0.450 |
Why?
| | Humans | 43 | 2023 | 32988 | 0.450 |
Why?
| | Aged | 22 | 2023 | 10542 | 0.430 |
Why?
| | Cyclophosphamide | 9 | 2021 | 65 | 0.430 |
Why?
| | Necrobiotic Xanthogranuloma | 1 | 2011 | 1 | 0.430 |
Why?
| | Plasma Cells | 1 | 2011 | 9 | 0.430 |
Why?
| | Mediastinum | 1 | 2011 | 8 | 0.420 |
Why?
| | Lymphoma, Mantle-Cell | 1 | 2011 | 15 | 0.410 |
Why?
| | Male | 25 | 2022 | 17726 | 0.400 |
Why?
| | Leukemia, Lymphocytic, Chronic, B-Cell | 3 | 2022 | 20 | 0.400 |
Why?
| | Doxorubicin | 7 | 2021 | 60 | 0.390 |
Why?
| | Arsenicals | 2 | 2007 | 8 | 0.380 |
Why?
| | Oxides | 2 | 2007 | 14 | 0.380 |
Why?
| | Cranial Irradiation | 2 | 2007 | 17 | 0.370 |
Why?
| | Vincristine | 7 | 2019 | 38 | 0.360 |
Why?
| | Prednisone | 7 | 2019 | 78 | 0.350 |
Why?
| | Female | 26 | 2021 | 18423 | 0.350 |
Why?
| | Aged, 80 and over | 11 | 2023 | 5249 | 0.350 |
Why?
| | Lymphohistiocytosis, Hemophagocytic | 1 | 2008 | 8 | 0.340 |
Why?
| | Cachexia | 2 | 2019 | 15 | 0.330 |
Why?
| | Disease-Free Survival | 7 | 2021 | 228 | 0.320 |
Why?
| | Kaplan-Meier Estimate | 5 | 2021 | 216 | 0.320 |
Why?
| | Leukemia, Myelomonocytic, Acute | 1 | 2007 | 1 | 0.310 |
Why?
| | Sarcoma, Myeloid | 1 | 2007 | 4 | 0.310 |
Why?
| | Ear Neoplasms | 1 | 2007 | 6 | 0.310 |
Why?
| | Lymphoproliferative Disorders | 2 | 2023 | 21 | 0.310 |
Why?
| | Epstein-Barr Virus Infections | 2 | 2023 | 18 | 0.300 |
Why?
| | Recurrence | 6 | 2020 | 400 | 0.290 |
Why?
| | Purpura, Thrombotic Thrombocytopenic | 1 | 2006 | 9 | 0.290 |
Why?
| | Drug Administration Schedule | 6 | 2019 | 249 | 0.280 |
Why?
| | Brain Neoplasms | 2 | 2006 | 178 | 0.280 |
Why?
| | Combined Modality Therapy | 4 | 2019 | 449 | 0.260 |
Why?
| | Immunotherapy | 2 | 2008 | 75 | 0.250 |
Why?
| | Lymphomatoid Granulomatosis | 1 | 2003 | 3 | 0.250 |
Why?
| | Prognosis | 6 | 2021 | 1011 | 0.240 |
Why?
| | HIV Infections | 2 | 2021 | 1000 | 0.240 |
Why?
| | Lymphoma, B-Cell | 3 | 2008 | 16 | 0.240 |
Why?
| | Proto-Oncogene Proteins c-myc | 2 | 2021 | 28 | 0.230 |
Why?
| | Remission Induction | 6 | 2015 | 111 | 0.220 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 3 | 2011 | 29 | 0.210 |
Why?
| | Drug Resistance, Neoplasm | 3 | 2020 | 81 | 0.200 |
Why?
| | Thrombosis | 1 | 2021 | 74 | 0.200 |
Why?
| | Benzylidene Compounds | 1 | 2020 | 2 | 0.190 |
Why?
| | Azepines | 1 | 2020 | 6 | 0.190 |
Why?
| | Multiple Myeloma | 1 | 2020 | 36 | 0.190 |
Why?
| | Graft vs Host Disease | 1 | 2020 | 60 | 0.180 |
Why?
| | Folic Acid Deficiency | 1 | 2019 | 8 | 0.180 |
Why?
| | Phthalazines | 1 | 2019 | 9 | 0.180 |
Why?
| | Central Nervous System | 3 | 2023 | 66 | 0.180 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2019 | 31 | 0.180 |
Why?
| | Respiratory Insufficiency | 1 | 2020 | 61 | 0.180 |
Why?
| | Retrospective Studies | 5 | 2023 | 3835 | 0.180 |
Why?
| | Proportional Hazards Models | 2 | 2017 | 387 | 0.170 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2020 | 128 | 0.170 |
Why?
| | Neutropenia | 4 | 2012 | 25 | 0.170 |
Why?
| | Young Adult | 4 | 2021 | 2287 | 0.170 |
Why?
| | Cytosine | 2 | 2021 | 8 | 0.170 |
Why?
| | Piperazines | 1 | 2019 | 96 | 0.170 |
Why?
| | Medical Oncology | 1 | 2018 | 37 | 0.160 |
Why?
| | Neoplasm Recurrence, Local | 3 | 2021 | 244 | 0.160 |
Why?
| | Kidney Diseases | 1 | 2019 | 152 | 0.150 |
Why?
| | Immunity | 1 | 2017 | 26 | 0.150 |
Why?
| | Cardiology | 1 | 2018 | 115 | 0.150 |
Why?
| | Immunocompromised Host | 1 | 2017 | 54 | 0.150 |
Why?
| | Stroke Volume | 1 | 2016 | 67 | 0.150 |
Why?
| | Biopsy | 2 | 2019 | 277 | 0.140 |
Why?
| | Registries | 1 | 2017 | 226 | 0.140 |
Why?
| | Feasibility Studies | 2 | 2019 | 282 | 0.140 |
Why?
| | Induction Chemotherapy | 1 | 2015 | 14 | 0.140 |
Why?
| | Hematologic Neoplasms | 1 | 2014 | 20 | 0.130 |
Why?
| | Myelodysplastic Syndromes | 2 | 2004 | 40 | 0.120 |
Why?
| | Leukopenia | 2 | 2011 | 9 | 0.120 |
Why?
| | Herpesvirus 4, Human | 2 | 2023 | 17 | 0.120 |
Why?
| | Lymphoma, Follicular | 2 | 2011 | 10 | 0.120 |
Why?
| | Methotrexate | 2 | 2023 | 47 | 0.120 |
Why?
| | Transcription Factors | 2 | 2004 | 176 | 0.110 |
Why?
| | Cytarabine | 3 | 2023 | 13 | 0.110 |
Why?
| | Daunorubicin | 2 | 2015 | 4 | 0.110 |
Why?
| | Hemoglobinuria, Paroxysmal | 1 | 2012 | 7 | 0.110 |
Why?
| | Transcriptome | 1 | 2012 | 90 | 0.110 |
Why?
| | DNA-Binding Proteins | 2 | 2004 | 278 | 0.110 |
Why?
| | Agranulocytosis | 1 | 2011 | 7 | 0.110 |
Why?
| | Yttrium Radioisotopes | 1 | 2011 | 7 | 0.100 |
Why?
| | Lymphoma, B-Cell, Marginal Zone | 1 | 2011 | 9 | 0.100 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2014 | 230 | 0.100 |
Why?
| | Fatal Outcome | 2 | 2008 | 76 | 0.100 |
Why?
| | Retreatment | 1 | 2010 | 16 | 0.100 |
Why?
| | Obesity | 1 | 2014 | 359 | 0.100 |
Why?
| | Salvage Therapy | 1 | 2010 | 48 | 0.100 |
Why?
| | Cytokines | 1 | 2012 | 372 | 0.100 |
Why?
| | Platelet Count | 2 | 2007 | 23 | 0.090 |
Why?
| | Pilot Projects | 1 | 2011 | 466 | 0.090 |
Why?
| | Infusions, Intravenous | 2 | 2020 | 87 | 0.080 |
Why?
| | Tretinoin | 1 | 2007 | 19 | 0.080 |
Why?
| | Weight Loss | 2 | 2019 | 116 | 0.080 |
Why?
| | Injections, Spinal | 1 | 2007 | 48 | 0.080 |
Why?
| | Vascular Neoplasms | 1 | 2006 | 3 | 0.070 |
Why?
| | Tomography, X-Ray Computed | 1 | 2011 | 899 | 0.070 |
Why?
| | Plasma Exchange | 1 | 2006 | 20 | 0.070 |
Why?
| | Follow-Up Studies | 1 | 2011 | 2053 | 0.070 |
Why?
| | ADAM Proteins | 1 | 2006 | 92 | 0.070 |
Why?
| | Hemoglobins | 1 | 2006 | 85 | 0.070 |
Why?
| | Immunosuppressive Agents | 2 | 2023 | 166 | 0.070 |
Why?
| | Twins, Dizygotic | 1 | 2005 | 4 | 0.070 |
Why?
| | Autoantibodies | 1 | 2006 | 119 | 0.070 |
Why?
| | Severity of Illness Index | 2 | 2021 | 1242 | 0.070 |
Why?
| | Survival Analysis | 2 | 2019 | 372 | 0.070 |
Why?
| | Proto-Oncogenes | 1 | 2004 | 5 | 0.070 |
Why?
| | Radiography | 1 | 2007 | 717 | 0.070 |
Why?
| | Thalidomide | 1 | 2004 | 7 | 0.070 |
Why?
| | Etoposide | 2 | 2019 | 64 | 0.060 |
Why?
| | Peripheral Blood Stem Cell Transplantation | 1 | 2004 | 7 | 0.060 |
Why?
| | Kidney Transplantation | 1 | 2006 | 153 | 0.060 |
Why?
| | Cohort Studies | 2 | 2021 | 2077 | 0.060 |
Why?
| | Antigens, CD20 | 1 | 2003 | 8 | 0.060 |
Why?
| | Epilepsy, Tonic-Clonic | 1 | 2003 | 9 | 0.060 |
Why?
| | Vision Disorders | 1 | 2003 | 24 | 0.060 |
Why?
| | Antigens, Neoplasm | 1 | 2003 | 44 | 0.060 |
Why?
| | Cyclin D1 | 1 | 2003 | 4 | 0.060 |
Why?
| | Cell Cycle Proteins | 1 | 2003 | 19 | 0.060 |
Why?
| | United States | 2 | 2021 | 2632 | 0.060 |
Why?
| | K562 Cells | 1 | 2003 | 7 | 0.060 |
Why?
| | Telomerase | 1 | 2003 | 10 | 0.060 |
Why?
| | Histones | 1 | 2003 | 32 | 0.060 |
Why?
| | Voriconazole | 1 | 2022 | 9 | 0.050 |
Why?
| | Sulfonamides | 1 | 2022 | 60 | 0.050 |
Why?
| | Apoptosis | 1 | 2003 | 288 | 0.050 |
Why?
| | Cerebral Cortex | 1 | 2003 | 206 | 0.050 |
Why?
| | Azacitidine | 1 | 2021 | 13 | 0.050 |
Why?
| | L-Lactate Dehydrogenase | 1 | 2021 | 9 | 0.050 |
Why?
| | Gene Rearrangement | 1 | 2021 | 16 | 0.050 |
Why?
| | Risk Factors | 2 | 2005 | 2762 | 0.050 |
Why?
| | Thrombocytopenia | 2 | 2012 | 31 | 0.050 |
Why?
| | Incidence | 1 | 2023 | 840 | 0.050 |
Why?
| | Activities of Daily Living | 1 | 2023 | 515 | 0.050 |
Why?
| | Folic Acid | 1 | 2019 | 25 | 0.050 |
Why?
| | Monoclonal Gammopathy of Undetermined Significance | 1 | 2019 | 2 | 0.040 |
Why?
| | Maintenance Chemotherapy | 1 | 2019 | 4 | 0.040 |
Why?
| | Kidney Function Tests | 1 | 2019 | 28 | 0.040 |
Why?
| | Maximum Tolerated Dose | 1 | 2019 | 16 | 0.040 |
Why?
| | Immunoglobulin A | 1 | 2019 | 20 | 0.040 |
Why?
| | Translocation, Genetic | 1 | 2019 | 11 | 0.040 |
Why?
| | Symptom Assessment | 1 | 2019 | 24 | 0.040 |
Why?
| | Vidarabine | 2 | 2011 | 13 | 0.040 |
Why?
| | Transplantation, Homologous | 1 | 2020 | 297 | 0.040 |
Why?
| | Anemia | 2 | 2012 | 98 | 0.040 |
Why?
| | Postoperative Complications | 1 | 2006 | 1117 | 0.040 |
Why?
| | Sarcopenia | 1 | 2019 | 34 | 0.040 |
Why?
| | Body Composition | 1 | 2019 | 78 | 0.040 |
Why?
| | Mitoxantrone | 2 | 2011 | 5 | 0.040 |
Why?
| | Interdisciplinary Communication | 1 | 2018 | 31 | 0.040 |
Why?
| | Ovarian Neoplasms | 1 | 2019 | 80 | 0.040 |
Why?
| | Magnetic Resonance Imaging | 1 | 2003 | 1315 | 0.040 |
Why?
| | Disease Management | 1 | 2019 | 138 | 0.040 |
Why?
| | Lung Neoplasms | 1 | 2003 | 745 | 0.040 |
Why?
| | Sex Factors | 1 | 2019 | 548 | 0.040 |
Why?
| | Tomography, Emission-Computed | 2 | 2006 | 13 | 0.040 |
Why?
| | Neoplasms | 1 | 2019 | 280 | 0.040 |
Why?
| | Prospective Studies | 2 | 2015 | 2002 | 0.040 |
Why?
| | Recombinant Proteins | 2 | 2008 | 289 | 0.040 |
Why?
| | Disease Progression | 2 | 2012 | 870 | 0.030 |
Why?
| | Naphthalimides | 1 | 2015 | 2 | 0.030 |
Why?
| | Organophosphonates | 1 | 2015 | 5 | 0.030 |
Why?
| | Adenine | 1 | 2015 | 6 | 0.030 |
Why?
| | Lipid Metabolism | 1 | 2014 | 47 | 0.030 |
Why?
| | Sensitivity and Specificity | 2 | 2006 | 592 | 0.030 |
Why?
| | Adolescent | 1 | 2021 | 2687 | 0.030 |
Why?
| | Insulin Resistance | 1 | 2014 | 72 | 0.030 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2004 | 178 | 0.030 |
Why?
| | Cytogenetic Analysis | 1 | 2012 | 5 | 0.030 |
Why?
| | Administration, Oral | 1 | 2012 | 158 | 0.030 |
Why?
| | RNA, Messenger | 2 | 2003 | 376 | 0.030 |
Why?
| | Pneumonia | 1 | 2012 | 75 | 0.030 |
Why?
| | Signal Transduction | 1 | 2014 | 590 | 0.030 |
Why?
| | Radiopharmaceuticals | 1 | 2011 | 57 | 0.030 |
Why?
| | Time Factors | 1 | 2015 | 1873 | 0.020 |
Why?
| | Nausea | 1 | 2007 | 26 | 0.020 |
Why?
| | Methylprednisolone | 1 | 2007 | 22 | 0.020 |
Why?
| | Creatinine | 1 | 2007 | 59 | 0.020 |
Why?
| | Cisplatin | 1 | 2007 | 106 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2006 | 494 | 0.020 |
Why?
| | Zinc Fingers | 1 | 2004 | 10 | 0.020 |
Why?
| | Animals | 1 | 2014 | 5371 | 0.020 |
Why?
| | Cell Lineage | 1 | 2004 | 34 | 0.020 |
Why?
| | Spleen | 1 | 2004 | 52 | 0.020 |
Why?
| | Teniposide | 1 | 2004 | 2 | 0.020 |
Why?
| | Bleomycin | 1 | 2004 | 4 | 0.020 |
Why?
| | Drug Therapy, Combination | 1 | 2004 | 261 | 0.020 |
Why?
| | S Phase | 1 | 2003 | 12 | 0.020 |
Why?
| | E2F Transcription Factors | 1 | 2003 | 5 | 0.020 |
Why?
| | E2F1 Transcription Factor | 1 | 2003 | 5 | 0.020 |
Why?
| | Interferon-alpha | 1 | 2004 | 69 | 0.020 |
Why?
| | Neoplasm Staging | 1 | 2005 | 457 | 0.020 |
Why?
| | Retinoblastoma Protein | 1 | 2003 | 11 | 0.020 |
Why?
| | Karyotyping | 1 | 2003 | 13 | 0.020 |
Why?
| | Transplantation, Autologous | 1 | 2004 | 221 | 0.010 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2003 | 38 | 0.010 |
Why?
| | DNA Primers | 1 | 2003 | 61 | 0.010 |
Why?
| | Granulocytes | 1 | 2003 | 25 | 0.010 |
Why?
| | Patient Selection | 1 | 2005 | 261 | 0.010 |
Why?
| | Cell Nucleus | 1 | 2003 | 86 | 0.010 |
Why?
| | Bone Marrow Cells | 1 | 2003 | 65 | 0.010 |
Why?
| | Transcription, Genetic | 1 | 2003 | 129 | 0.010 |
Why?
| | Blotting, Western | 1 | 2003 | 218 | 0.010 |
Why?
| | Polymerase Chain Reaction | 1 | 2003 | 184 | 0.010 |
Why?
| | Bone Marrow | 1 | 2003 | 75 | 0.010 |
Why?
| | Acute Disease | 1 | 2003 | 258 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 2003 | 471 | 0.010 |
Why?
|
|
Venugopal's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|